Immunome provides update, sees recent transactions improving ADC capabilities

Immunome provided an update on recent business development activity, including three recently closed transactions that are expected to enhance the company’s antibody-drug conjugate or ADC capabilities. Immunome acquired worldwide, exclusive rights to: A panel of antibodies against an undisclosed solid tumor target from Nectin Therapeutics; A panel of antibodies against an undisclosed solid tumor target from Bluefin Biomedicine; Four antibodies against undisclosed targets from OncoResponse; In addition, the company previously announced the purchase of 28 antibodies from Atreca in May 2024 and the exclusive license of IM-1021 along with the underlying ADC platform technology from Zentalis in January 2024. None of the acquired antibodies are known to share the same target as an FDA approved ADC. “Immunome’s long-term vision remains centered on a broad pipeline of targeted therapies, particularly ADCs against novel targets,” said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “Focused business development activity complements our highly productive internal discovery efforts and has led to an advancing pipeline of product candidates.”